Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer.

Yasmin Leshem,Yardenna Dolev,Nava Siegelmann-Danieli,Sarah Sharman Moser,Lior Apter,Gabriel Chodick,Alla Nikolaevski-Berlin,Sivan Shamai,Ofer Merimsky,Ido Wolf

Cancer（2023）

引用 5|浏览9

暂无评分

摘要

This study suggests immunotherapy is less beneficial in diabetic NSCLC patients. More work is needed to verify our findings and explore similar effects in other cancer entities.

查看译文

关键词

diabetes mellitus, immunotherapy, NSCLC, PD-1, pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要